GMAB

Genmab A/S ADS
D

GMAB

Arincen61/100B

Genmab A earnings

Genmab A/S ADS reports its Q4 FY2026 results on 16 February 2027. Analysts expect earnings per share of 0.23 USD and revenue of 1.25B USD.

In Q3 FY2026, reported on 5 November 2026, Genmab A/S ADS earned 0.56 USD a share against the 0.36 USD analysts expected (+55.6%), on revenue of 1.19B USD against 1.20B USD (-0.9%).

Last EPS surprise
+55.6%
Last revenue surprise
-0.9%
Move after the last report
+1.8%
Average move after earnings
2.6%

EPS and revenue against estimates

Next earnings · Q4 FY2026
EPS estimate
0.23 USD
Revenue estimate
1.25B USD
Last quarter · Q3 FY2026
EPS0.56Beat +55.6%Revenue1.19BMissed -0.9%

Revenue

ReportedEstimate

EPS

ReportedEstimate
PeriodReport dateEPS estimateReported EPSSurpriseEPS growthRevenue estimateReported revenueSurpriseRevenue growthNext-day move
Q1 FY20270.20——+126.00%1.11B——+24.26%—
Q4 FY20260.23——+360.00%1.25B——+18.37%—
Q3 FY20260.360.56+55.56%-13.85%1.20B1.19B-0.92%+16.14%+1.8%
Q2 FY20260.370.54+45.95%0.00%1.12B1.16B+3.46%+24.89%+4.7%
Q1 FY20260.150.09-42.00%-71.94%905.77M896.00M-1.08%+23.42%-2.3%
Q4 FY20250.460.05-89.13%-91.23%1.07B1.06B-0.76%+18.11%-2.7%
Q3 FY20250.480.65+35.42%+124.14%1.01B1.02B+1.08%+25.37%-0.6%
Q2 FY20250.390.54+38.46%+145.45%952.56M924.81M-2.91%+17.13%-5.6%
Q1 FY20250.230.31+34.78%+93.75%755.47M725.99M-3.90%+21.39%-0.2%
Q4 FY20240.360.57+58.33%+58.33%894.71M895.80M+0.12%+32.65%+6.2%
Q3 FY20240.350.29-17.14%-38.30%809.62M815.16M+0.68%+21.78%+3.5%
Q2 FY20240.290.22-24.14%-26.67%732.47M789.59M+7.80%+28.75%-2.2%
Q1 FY20240.160.160.00%+220.00%572.03M598.08M+4.55%+43.74%+7.4%
Q4 FY20230.340.36+5.88%+200.00%671.21M675.34M+0.62%-10.55%+2.3%
Q3 FY20233.140.47-85.03%-11.32%642.86M669.38M+4.13%+24.97%+4.9%
Q2 FY20232.180.30-86.24%-26.83%601.13M613.29M+2.02%+38.13%-4.9%
Q1 FY20230.650.05-92.31%-54.55%404.26M416.08M+2.92%+32.03%+4.1%
Q4 FY20223.150.12-96.19%-29.41%681.42M754.97M+10.79%+89.14%-1.6%
Q3 FY20221.650.53-67.88%+152.38%473.49M535.64M+13.13%+48.62%+5.3%
Q2 FY20221.550.41-73.55%+412.50%412.04M443.98M+7.75%+41.24%+5.6%
Q1 FY20220.910.11-87.91%-59.26%300.49M315.14M+4.88%+26.17%+0.7%
Q4 FY20215.300.17-96.79%+21.43%389.00M399.16M+2.61%+18.93%-2.6%
Q3 FY20210.110.21+90.91%+61.54%270.35M360.41M+33.31%+32.65%+2.1%
Q2 FY20210.080.080.00%-89.47%353.27M314.36M-11.02%-61.77%+3.4%
Q1 FY20210.230.27+17.39%+350.00%214.32M249.78M+16.54%+92.40%+1.5%
Q4 FY20201.280.14-89.06%-58.82%563.55M335.62M-40.44%-25.33%-4.2%
Q3 FY20200.990.13-86.87%-89.68%459.63M271.70M-40.89%+78.25%+3.8%
Q2 FY20200.880.76-13.64%+280.00%231.81M822.37M+254.76%+599.34%+4.0%
Q1 FY20200.060.06+3.45%—763.51M129.82M-83.00%—+4.9%
Q4 FY20190.360.34-5.56%+57.77%430.54M449.49M+4.40%+126.65%+3.1%
Q3 FY20190.081.26+1,475.00%+2,690.08%195.69M152.42M-22.11%+62.97%+0.3%
Q2 FY20190.270.20-25.93%+205.16%144.85M117.59M-18.82%+48.21%+0.9%
Q4 FY2018—0.02—-91.16%—88.87M—-44.56%+2.2%
Q4 FY2018—0.22—+8.35%—198.32M—+23.71%-5.3%
Q3 FY2018—0.05———93.53M—+82.86%+2.1%
Q2 FY2018—0.07—-13.56%—79.34M—-33.02%-0.6%
Q4 FY2017—0.05—-72.42%—112.55M—-13.97%-1.3%
Q4 FY2017—0.20—+3.70%—160.31M—+22.53%+3.4%
Q3 FY2017—-0.00—-103.08%—51.15M—-6.81%+1.4%
Q2 FY2017—0.08—+86.66%—118.46M—+124.21%-0.9%
Q4 FY2016—0.00—-96.09%—36.09M—-56.93%-5.9%
Q4 FY2016—0.19—+100.73%—130.83M—+56.13%+3.7%
Q3 FY2016—0.05—+33.47%—54.88M—+31.68%0.0%
Q2 FY2016—0.04—+912.97%—52.83M—+104.55%+0.9%
Q4 FY2015—-0.00—-113.95%—25.94M—-30.95%+1.0%
Q4 FY2015—0.10—+359.60%—83.80M—+123.07%+0.4%
Q3 FY2015—0.03—-26.78%—41.68M—-9.45%+2.2%
Q2 FY2015—0.00———25.83M—+21.94%+0.8%
Q4 FY2014—0.05—+164.75%—15.51M—-59.59%-1.6%
Q4 FY2014—0.02—+4.11%—37.57M—-2.11%+3.1%
Q3 FY2014—0.05—+2,489.56%—46.03M—+69.10%+0.2%
Q2 FY2014—-0.01———21.18M—-12.04%0.0%
Q4 FY2013—0.03———45.44M—+61.11%-2.2%
Q4 FY2013—0.02———38.38M—+36.08%+1.5%
Q3 FY2013—0.00———27.22M—+36.18%+0.5%
Q2 FY2013—-0.01———24.08M—+28.44%0.0%
Q4 FY2012—0.02———27.43M—+68.47%+5.4%
Q4 FY2012—-0.13———28.20M—+73.19%0.0%
Q3 FY2012—-0.02———19.99M—+21.78%0.0%
Q2 FY2012—-0.00———18.75M—+15.43%0.0%
Q4 FY2011—-0.03———16.79M—+3.78%0.0%
Q4 FY2011—-0.02———16.28M—+0.63%0.0%
Q3 FY2011—-0.15———16.41M—-58.15%0.0%
Q2 FY2011—-0.03———16.24M—-42.53%0.0%
Q4 FY2010—-0.05———15.76M—-57.53%0.0%
Q4 FY2010—-0.03———16.18M—-56.39%0.0%
Q3 FY2010—-0.01———39.23M—+190.50%0.0%
Q2 FY2010—-0.03———28.27M—+103.12%-27.0%
Q4 FY2009—-0.05———19.27M—-56.98%0.0%
Q4 FY2009—-0.26———37.11M—-17.16%+10.6%
Q3 FY2009—-0.04———13.50M——0.0%
Q2 FY2009—-0.05———13.92M——0.0%
Q4 FY2008—-0.08———44.80M———

The move is the shares' change on the trading day after the report: after a report after the close, the next day's close on the report day's; before the open, the report day's close on the day before's. Surprise is the reported figure against the analysts' average estimate.

Beat record

On average, analysts' EPS estimate was 37.2% off the result, either way, and their revenue estimate 2.3%, over the last 12 quarters.

EPS beats
11 / 30
Revenue beats
19 / 30
Average EPS surprise, last 12
+8.5%
Since
August 2019

See also:Forecast,EPS,Income statement

Common questions about Genmab A's earnings

Source: Financial Modeling Prep